Zanzalintinib

• CAT Number: I038431
• CAS Number: 2367004-54-2
• Molecular Formula: C29H25FN4O5
• Molecular Weight: 528.53
• Purity: ≥95%
• Synonyms: 1-N’-(4-fluorophenyl)-1-N-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide
• IUPAC Name: 1-N'-(4-fluorophenyl)-1-N-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide
• InChI: InChI=1S/C29H25FN4O5/c1-31-26(35)22-15-21-23(16-25(22)38-2)32-14-11-24(21)39-20-9-7-19(8-10-20)34-28(37)29(12-13-29)27(36)33-18-5-3-17(30)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,35)(H,33,36)(H,34,37)
• InChIKey: JSPCKALGNNVYOO-UHFFFAOYSA-N
• SMILES: CNC(=O)C1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F

Zanzalintinib (Cat No.:I038431) is an oral, multi-targeted tyrosine kinase inhibitor designed to block key oncogenic pathways. It selectively inhibits kinases such as MET, VEGFR2, AXL, and MER, which are implicated in tumor growth, angiogenesis, metastasis, and immune evasion. Zanzalintinib demonstrates potent antitumor activity across various cancer models, including renal cell carcinoma and other solid tumors. Its broad-spectrum kinase inhibition supports both direct tumor suppression and immune modulation. Zanzalintinib is under clinical investigation as a monotherapy and in combination with immune checkpoint inhibitors for advanced malignancies.